Hattori Nobutaka, Arano Taku, Hatano Taku, Mori Akio, Imai Yuzuru
Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo, 113-8421, Japan.
Adv Exp Med Biol. 2017;997:157-169. doi: 10.1007/978-981-10-4567-7_12.
Parkinson's disease (PD) is a common neurodegenerative disorder, with ageing being a major risk factor. Accordingly, estimates predict an increasing number of PD patients due to our expanding life span. Consequently, developing a true disease-modifying therapy is necessary. In this regard, monogenic PD offers a suitable means for determining pathogenesis. Among monogenic forms of PD, mitochondrial dysfunction may be a major cause and is also likely to be involved in sporadic PD. Thus, mitochondrial impairment may be a common pathway. Recently, mitochondria-associated membranes (MAM) were identified as dynamic sites between mitochondria and endoplasmic reticulum. Indeed, the gene product of α-synuclein is a major component of MAM, with other gene products also involved. This review focuses on the possibility of using MAM as novel therapeutic targets.
帕金森病（PD）是一种常见的神经退行性疾病，衰老为主要风险因素。因此，据估计，随着人类寿命的延长，帕金森病患者数量将会增加。所以，开发真正能改变疾病进程的疗法很有必要。在这方面，单基因帕金森病为确定发病机制提供了合适的途径。在单基因形式的帕金森病中，线粒体功能障碍可能是主要病因，也可能参与散发性帕金森病的发病过程。因此，线粒体损伤可能是一个共同的发病途径。最近，线粒体相关膜（MAM）被确定为线粒体与内质网之间的动态位点。实际上，α-突触核蛋白的基因产物是MAM的主要成分，其他基因产物也有参与。本综述重点探讨将MAM作为新型治疗靶点的可能性。
